- Report
- April 2025
- 175 Pages
Global
From €4112EUR$4,490USD£3,501GBP
- Report
- October 2024
- 191 Pages
Global
From €3247EUR$3,545USD£2,764GBP
€3607EUR$3,939USD£3,071GBP
- Report
- October 2024
- 193 Pages
Global
From €3247EUR$3,545USD£2,764GBP
€3607EUR$3,939USD£3,071GBP
- Report
- March 2025
- 200 Pages
Global
From €4112EUR$4,490USD£3,501GBP
- Report
- May 2025
- 250 Pages
Global
From €5358EUR$5,850USD£4,561GBP
- Report
- April 2025
- 130 Pages
Global
From €4350EUR$4,750USD£3,704GBP
- Report
- May 2024
- 75 Pages
Global
From €9154EUR$9,995USD£7,793GBP
- Report
- February 2023
- 120 Pages
Global
From €4121EUR$4,500USD£3,509GBP
- Report
- June 2023
- 180 Pages
Global
From €4532EUR$4,949USD£3,859GBP
- Report
- May 2023
- 160 Pages
Global
From €4532EUR$4,949USD£3,859GBP
- Report
- April 2023
- 117 Pages
Global
From €4350EUR$4,750USD£3,704GBP
- Report
- September 2021
- 141 Pages
Global
From €4075EUR$4,450USD£3,470GBP
- Book
- December 2018
- 424 Pages
- Book
- October 2022
North America

The Lung Injury market within the context of Pulmonary Medicine is a rapidly growing field of medical research and treatment. It is focused on the diagnosis and management of diseases and conditions that affect the lungs, such as asthma, COPD, and interstitial lung disease. Treatment options for lung injury include medications, oxygen therapy, and surgery. Research is ongoing to develop new treatments and therapies for lung injury.
The Lung Injury market is a highly competitive field, with many companies offering products and services to treat and manage lung injury. Companies such as GlaxoSmithKline, Boehringer Ingelheim, and AstraZeneca are leading the way in developing new treatments and therapies for lung injury. Other companies such as Novartis, Merck, and Pfizer are also active in the Lung Injury market, offering products and services to help patients manage their condition. Show Less Read more